Clinical trials: Amlodipine
Hypertension
Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to ARB monoTHerapy Using 24h ABPM
A majority of Korean doctors tend to add other antihypertensive rather than to titrate the same drug. However, we try to induce doctors to titrate the Sevikar than to add other antihypertensive if patients are not controlled with…
- Trial name
- EARTH (NCT01713920)
- Testing
- SEVIKAR
- Where
- 2 sites in South Korea
- Volunteers
- 68 people
- Sponsor
- Sang Hyun Ihm, MD PhD
Nonalcoholic Fatty Liver Disease (NAFLD)
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
The aim of this current study was to assess the therapeutic effects of perindopril and telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic effects of these two kind of drugs.
- Trial name
- NF-NAFLD (NCT02213224)
- Testing
- Perindopril, Telmisartan, Amlodipine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Ischemic Stroke, Hypertension
Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance
BOSS-Trial I is a phase 2 clinical trial with the following objectives; 1. to prove the feasibility of a Bluetooth-equipped sphygmomanometer system in real-world clinical practice and wireless connection to the main server; 2.
- Trial name
- NCT03024476
- Testing
- Behavioral intensification, Pharmacological intensification based on olmesartan, Bluetooth-equipped sphygmomanometer
- Where
- 3 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- Seoul National University Bundang Hospital
JNC 7 Stage 1 or 2 Hypertension
Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine
Study is to evaluate the effect of Nebivolol to treat high blood pressure compared to an already approved drug, Metoprolol ER with background treatment of Amlodipine.
- Trial name
- NCT03635125
- Testing
- Nebivolol I, Nebivolol II, Baseline Washout Phase
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Trinity Hypertension & Metabolic Research Institute
Cognitively Normal Older Adults, Hypertension
Risk Reduction for Alzheimer's Disease
Physical inactivity, high blood pressure and dyslipidemia are risk factors for Alzheimer's disease (AD) and vascular dementia. Importantly, these risk factors are modifiable with lifestyle changes, pharmacological treatment, or…
- Conditions
- Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
- Trial name
- rrAD (NCT02913664)
- Testing
- Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care
- Where
- 4 sites in United States
- Volunteers
- 513 people
- Sponsor
- University of Texas Southwestern Medical Center
Thalassemia, Iron Overload
Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
This study aims to investigate the use of amlodipine, a drug that blocks the uptake of calcium into cells, in the prevention and treatment of iron overload in patients with thalassemia major.
- Trial name
- AmloThal (NCT01395199)
- Testing
- Amlodipine
- Where
- Brazil
- Volunteers
- 62 people
- Sponsor
- University of Campinas, Brazil
Hypertension
An Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets,China in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions
Amlodipine Besylate Controlled-release Tablets in Healthy Volunteers in a Randomized, Open, Two-cycle, Double-cross, Fasting State Comparative Pharmacokinetic Study.
- Trial name
- NCT05667818
- Testing
- Amlodipine besylate tablets (trade name: Norfloxacin ®）, Amlodipine besylate controlled-release tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Healthy Subjects
Bioequivalence Study of CJ-30060 in Healthy Volunteers
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.
- Trial name
- NCT03757390
- Testing
- Exforge® tab 5/160mg, Crestor® tab 10mg, CJ-30060 5/160/10mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Hypertension
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
- Trial name
- NCT00350168
- Testing
- valsartan + amlodipine
- Where
- United States
- Volunteers
- 647 people
- Sponsor
- Novartis
HYPERTENSION
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
A ONE YEAR SAFETY STUDY FOR PATIENTS WHO COMPLETE STUDY VAA489A2307.
- Trial name
- NCT00170976
- Testing
- valsartan + amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 403 people
- Sponsor
- Novartis
Hypertension
SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy
The goal of this clinical trial is to determine whether a renin-guided antihypertensive treatment strategy is feasible to implement in community primary care clinics and to explore whether spironolactone improves blood pressure…
- Trial name
- SPIRO-First (NCT07687160)
- Testing
- Spironolactone (drug), Candesartan 8mg, Hydrochlorothiazide (HCTZ) 25 milligrams.
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension
Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue
Hypertension is a leading risk factor for morbidity and mortality worldwide. The brain is a major target of the damaging effects of hypertension.
- Trial name
- NCT02996916
- Testing
- Olmesartan, Amlodipine
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kurume University
Angiotensin/Renin/Aldosterone Hypertension, Hypertension
Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension
In this study, we will assess the change of serum ACE-2, angiotensin(1-7), and vascular function after using olmesartan (an ARB), compared to conventional anti-hypertensive drug, amlodipine in hypertensive patients with T2DM.
- Conditions
- Angiotensin/Renin/Aldosterone Hypertension, Hypertension, Diabetes Mellitus, Type 2
- Trial name
- Ang(1-7) (NCT05189015)
- Testing
- Olmesartan
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Seoul National University Bundang Hospital
Hypertension
Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension
This trial is focusing on blood pressure control for patients with high blood pressure (hypertension) during the COVID-19 pandemic when seeing a doctor for advice may be difficult.
- Trial name
- PERSONALCovdBP (NCT04559074)
- Testing
- Amlodipine
- Where
- 2 sites in United Kingdom
- Volunteers
- 343 people
- Sponsor
- Queen Mary University of London
Hypertension
Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives
The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate on renal and vascular function in subjects with existing hypertension requiring antihypertensive therapy.
- Trial name
- NCT02979197
- Testing
- OE 10 mg amlodipine besylate tablet, OE 200 mg celecoxib capsule
- Where
- 9 sites in United Kingdom
- Volunteers
- 105 people
- Sponsor
- Kitov Pharma Ltd
Dyslipidemia With Hypertension
Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin
To evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with dyslipidemia with hypertension.
- Trial name
- NCT03088254
- Testing
- Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)
- Where
- 12 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hypertension
Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and amlodipine 5 mg…
- Trial name
- NCT01911780
- Testing
- telmisartan + HCTZ, amlodipine
- Where
- 17 sites in Japan
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension
This study was designed to compare the efficacy, tolerability, and safety of the combination valsartan/amlodipine 160/5 mg versus amlodipine 10 mg in patients with essential hypertension not adequately controlled (defined as mean…
- Trial name
- NCT00437645
- Testing
- Valsartan 160 mg capsules, Amlodipine 5 mg capsules
- Where
- 12 sites in Argentina, Chile and 10 more
- Volunteers
- 1,183 people
- Sponsor
- Novartis Pharmaceuticals
Masked Hypertension
Mechanism of Masked Hypertension - Intervention
To test the hypothesis that sympatholytic antihypertensive antihypertensive therapy (αβ-blocker - carvedilol) will reduce out-of-clinic ambulatory BP to a greater extent by blocking sympathetic activity than non-sympatholytic…
- Trial name
- NCT04121299
- Testing
- Carvedilol, Amlodipine
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Hypertension
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.
- Trial name
- NCT00219154
- Testing
- aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,125 people
- Sponsor
- Novartis